Literature DB >> 10199548

Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine.

.   

Abstract

OBJECTIVE: To present guidelines for hemodynamic support of adult patients with sepsis. PARTICIPANTS: An international task force of nine experts in disciplines related to critical care medicine was convened from the membership of the Society of Critical Care Medicine. EVIDENCE: Review of published literature and expertise and personal experience of task force. The strength of evidence of human studies was classified according to study design and scientific value. CONSENSUS PROCESS: The task force met several times in person and communicated by electronic mail to identify the pertinent literature and arrive at consensus recommendations. Consideration was given to the relationship between the weight of scientific evidence and the experts'opinions. Draft documents were composed and debated by the task force until consensus was reached. The strength of recommendations was graded according to evidenced-based guidelines.
CONCLUSIONS: The panel formulated an underlying approach to the hemodynamic support of sepsis. Hemodynamic therapies should be titrated to specific and definable endpoints. The effects of therapy should be assessed by monitoring a combination of parameters of global and regional perfusion. Using this approach, the panel made specific recommendations for fluid resuscitation, vasopressor therapy, and inotropic therapy of septic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199548     DOI: 10.1097/00003246-199903000-00049

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  55 in total

Review 1.  An approach to critically ill patients.

Authors:  R Rodriguez; H G Hern
Journal:  West J Med       Date:  2001-12

2.  Arterial pressure monitoring in septic shock.

Authors:  Frédéric Michard; Jean-Louis Teboul; Christian Richard; Yves Lecarpentier; Denis Chemla
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

3.  Think locally: evaluation of the microcirculation in sepsis.

Authors:  Steve M Hollenberg
Journal:  Intensive Care Med       Date:  2010-08-20       Impact factor: 17.440

Review 4.  Differential signaling in presynaptic neurotransmitter release.

Authors:  Wim E J M Ghijsen; A G Miriam Leenders
Journal:  Cell Mol Life Sci       Date:  2005-05       Impact factor: 9.261

Review 5.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.

Authors:  Emanuel P Rivers; Lauralyn McIntyre; David C Morro; Kandis K Rivers
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

6.  Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine.

Authors:  Yuji Kadoi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 7.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Protocolized approach to the management of congenital diaphragmatic hernia: benefits of reducing variability in care.

Authors:  Elisabeth T Tracy; Sarah E Mears; P Brian Smith; Melissa E Danko; Diana L Diesen; Kimberley A Fisher; Jeff C Hoehner; Ronald N Goldberg; C Michael Cotten; Henry E Rice
Journal:  J Pediatr Surg       Date:  2010-06       Impact factor: 2.545

9.  Impact of Norepinephrine Shortage on Outcomes in Patients with Septic Shock.

Authors:  Jean M Nappi; Adam Sieg; Tanna B Hassig; Amy E Wahlquist
Journal:  Res Rev J Hosp Clin Pharm       Date:  2016-05-12

Review 10.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Authors:  Hilmar Burchardi; Heinz Schneider
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.